SEC Form 4 · accession 0001140361-17-042137
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathryn C Zoon
Director
Period of report
Nov 8, 2017
Accepted (ET)
Nov 13, 2017 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4 | Nov 8, 2017 | S | 2,371 | $38.9443 | D | 20,114 | D | |
| Common StockF1,F2,F5 | Nov 8, 2017 | S | 371 | $40.8446 | D | 19,743 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of restricted stock units granted under the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
- F2The restricted stock units vest in three equal annual tranches beginning in November 2017.
- F3The transactions reported in this row were effected pursuant to a Rule 10b5-1 plan adopted by Dr. Zoon.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.25, inclusive.
- F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.84 to $40.85, inclusive.